Patrick W. McGarrah, M.D.

  1. Oncologist
  1. Baral B, Suleiman R, Fazer-Posorske CA, Ma DJ, McGarrah PW, Thome SD, Molina JR, Price KA, Halfdanarson TR, Fuentes HE. Advancing head and neck cancer management: Unveiling the diagnostic and therapeutic potentials of molecular profiling. Head Neck. 2024 Oct; 46 (10):E84-E90 Epub 2024 July 20
    View PubMed
  2. Suleiman R, McGarrah P, Baral B, Owen D, Vera Aguilera J, Halfdanarson TR, Price KA, Fuentes Bayne HE. Alpelisib and Immunotherapy: A Promising Combination for Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck. Cancer Rep (Hoboken). 2024 Oct; 7 (10):e70023
    View PubMed
  3. Rosenberg AJ, Perez CA, Guo W, de Oliveira Novaes JM, da Silva Reis KFO, McGarrah PW, Price KAR. Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy. Am Soc Clin Oncol Educ Book. 2024 Jun; 44 (3):e433330
    View PubMed
  4. Cooper AC, Fazer CA, Chintakuntlawar AV, Fuentes Bayne HE, McGarrah PW, Price KAR. Capecitabine for Salvage Treatment of Patients With Heavily Pretreated Human Papillomavirus-Associated Oropharynx Cancer With Distant Metastases. J Adv Pract Oncol. 2023 Nov; 14(7):571-575.
    View PubMed
  5. Andreatos N, McGarrah PW, Sonbol MB, Starr JS, Capdevila J, Sorbye H, Halfdanarson TR. Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment. Curr Oncol Rep. 2023 Oct; 25(10):1127-1139. Epub 2023 Aug 22.
    View PubMed
  6. Nathoo N, Gavrilova RH, Trejo-Lopez JA, McGarrah PW, Go RS, Alqallaf A, Tobin WO. Recurrent Tumefactive Central Nervous System Lesions Due to BRIP1 -Related Fanconi Anemia. Neurologist. 2023 Sep 1; 28 (5):332-334 Epub 2023 Sept 01
    View PubMed
  7. Algarin-Perneth S, Suleiman R, Abeykoon JP, Halfdanarson T, Fuentes-Bayne HE, Yi JE, Peikert T, McGarrah PW. Deep and Repeated Response to Trastuzumab Deruxtecan in a Patient With Human Epidermal Growth Factor Receptor 2-Amplified Large-Cell Neuroendocrine Carcinoma With Brain Metastases: A Case Report. JCO Precis Oncol. 2023 Sep; 7:e2300242.
    View PubMed
  8. Burkett BJ, Bartlett DJ, McGarrah PW, Lewis AR, Johnson DR, Berberoglu K, Pandey MK, Packard AT, Halfdanarson TR, Hruska CB, Johnson GB, Kendi AT. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements. Radiol Imaging Cancer. 2023 Jul; 5 (4):e220157
    View PubMed
  9. Le BK, McGarrah P, Paciorek A, Mohamed A, Apolo AB, Chan DL, Reidy-Lagunes D, Hauser H, Rivero JD, Whitman J, Batty K, Zhang L, Raj N, Le T, Bergsland E, Halfdanarson TR. Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review. Clin Genitourin Cancer. 2023 Jun; 21 (3):403-414.e5 Epub 2023 Mar 17
    View PubMed
  10. Gile JJ, McGarrah PW, Leventakos K, Sonbol MB, Starr JS, Eiring RA, Hobday TJ, Halfdanarson TR. Efficacy of first-line checkpoint inhibitors in combination with chemotherapy in high-grade extrapulmonary metastatic neuroendocrine carcinomas. J Neuroendocrinol. 2023 May; 35 (5):e13283 Epub 2023 May 25
    View PubMed
  11. McGarrah P, Hubbard J, Novotny PJ, Branda ME, Sargent DS, Morton RF, Fuchs CS, Benson AB, Williamson SK, Findlay BP, Alberts SR, Goldberg RM, Sloan JA. Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer. Cancer Control. 2023 Jan-Dec; 30:10732748231185047
    View PubMed
  12. Koleilat A, McGarrah PW, Olteanu H, Van Dyke DL, Smadbeck JB, Johnson SH, Vasmatzis G, Hoppman NL, Xu X, Ketterling RP, Greipp PT, Baughn LB, Patnaik MS, Peterson JF. Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t(4;12)(q12;p13) in the absence of ETV6/CHIC2 and ETV6/PDGFRA gene fusions. Cancer Genet. 2022 Jan; 260-261:1-5 Epub 2021 Nov 06
    View PubMed
  13. Chan DL, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, Kelly V, Kunz PL, McGarrah PW, Raj NP, Reidy DL, Thawer A, Whitman J, Wu L, Becker C, Singh S. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. Oncologist. 2021 Nov; 26 (11):950-955 Epub 2021 Aug 21
    View PubMed
  14. Liu AJ, Ueberroth BE, McGarrah PW, Buckner Petty SA, Kendi AT, Starr J, Hobday TJ, Halfdanarson TR, Sonbol MB. Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors. Oncologist. 2021 May; 26 (5):383-388 Epub 2021 Feb 08
    View PubMed
  15. Gile JJ, Liu AJ, McGarrah PW, Eiring RA, Hobday TJ, Starr JS, Sonbol MB, Halfdanarson TR. Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms: Mayo Clinic Experience. Pancreas. 2021 Apr 1; 50 (4):500-505
    View PubMed
  16. McGarrah PW, Westin GFM, Hobday TJ, Scales JA, Ingimarsson JP, Leibovich BC, Halfdanarson TR. Renal Neuroendocrine Neoplasms: A Single-center Experience. Clin Genitourin Cancer. 2020 Aug; 18 (4):e343-e349 Epub 2019 Dec 05
    View PubMed
  17. McGarrah PW, Leventakos K, Hobday TJ, Molina JR, Finnes HD, Westin GF, Halfdanarson TR. Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma. Pancreas. 2020 Apr; 49 (4):529-533
    View PubMed
  18. Guo Z, Johnson V, Barrera J, Porras M, Hinojosa D, Hernandez I, McGarrah P, Potter DA. Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them. Cancer Metastasis Rev. 2018 Sep; 37 (2-3):409-423
    View PubMed
  19. Zhang L, Kibaly C, Wang YJ, Xu C, Song KY, McGarrah PW, Loh HH, Liu JG, Law PY. Src-dependent phosphorylation of mu-opioid receptor at Tyr(336) modulates opiate withdrawal. EMBO Mol Med. 2017 Nov; 9 (11):1521-1536
    View PubMed